Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients

Status Completed

Clinical Trial Summary

To determine whether exercise and nutrition prehabilitation improves patient outcomes after cancer surgery

Clinical Trial Description

Preliminary qualitative and quantitative studies suggest that there are benefits (reduced length of stay, improved cardiorespiratory function, reduced postoperative complications and improved quality of life) when prehabilitation is used with the context of cancer care. In 2017 Macmillian Cancer Support developed a strategic 'Evidence and Insight' review on prehabilitation. The outcome of this was to incorporate prehabilitation into routine cancer care and to develop principles and guidance for prehabilitation. This study aims to support this vision and answer some of the questions on the patients who are most likely to benefit from prehabilitation and to quantify some of these benefits by investigating the molecular processes that influence clinical changes This study primarily seeks to assess the cardiovascular and biological impact of prehabilitation (exercise, nutrition) on patients undergoing hepatobiliary and colorectal cancer surgery. The investigators aim to assess whether there is an improvement in various cardiopulmonary exercise testing (CPET) variables such as maximum oxygen consumption and anaerobic threshold. The investigators also aim to study the inflammatory cytokines associated with cancer and how these markers respond to exercise. These inflammatory markers are thought to play a role in influencing some clinical outcomes such as wound infection and recovery. The study will also assess secondary outcomes including hospital stay, post operative complications and quality of life. The investigators aim to better understand the biological relationship between anti-inflammatory cytokine levels and the previously mentioned outcomes by measuring and analysing these mediators and performing selected muscle biopsies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04880772
Study type	Interventional
Source	East Lancashire Hospitals NHS Trust
Contact
Status	Completed
Phase	N/A
Start date	July 15, 2021
Completion date	July 13, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03781934` - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations	Phase 1/Phase 2
Completed	`NCT02107755` - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma	Phase 2
Recruiting	`NCT05057052` - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis	Phase 2
Recruiting	`NCT06120127` - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Phase 2
Recruiting	`NCT04837885` - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases	Phase 2
Terminated	`NCT04589884` - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting	`NCT04520737` - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases	N/A
Terminated	`NCT02465112` - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor	Phase 3
Completed	`NCT02352259` - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II	Phase 2
Active, not recruiting	`NCT01763450` - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer	Phase 2
Withdrawn	`NCT01631539` - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC	N/A
Recruiting	`NCT01250158` - Liver-PILP First-in-Man	N/A
Terminated	`NCT01233544` - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases	Phase 3
Completed	`NCT01347333` - Stereotactic Body Radiotherapy for Liver Tumors	N/A
Completed	`NCT00587756` - Alternative to Two-Stage Hepatectomy	N/A
Completed	`NCT01683357` - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases	N/A
Completed	`NCT04942665` - Low Dose ICG for Biliary Tract and Tumor Imaging	Phase 2
Not yet recruiting	`NCT05354674` - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting	`NCT04616495` - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting	`NCT04509635` - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Comparing Standard Care Versus Prehabilitation in Patients Undergoing Cancer Surgery — SPECS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms